Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience
The aim of this study was to evaluate the antidiabetic therapy during hospitalization, as well as that recommended at discharge from a single university endocrinology clinic for all type 2 diabetes patients admitted over a 12-month period. Of the 464 cases, 345 (74.4%) were emergency admissions and...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2025-07-01
|
| Series: | Pharmacia |
| Online Access: | https://pharmacia.pensoft.net/article/163319/download/pdf/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849415882353147904 |
|---|---|
| author | Mira Siderova Georgi Shopov Gabriela Kehayova Stela Dragomanova |
| author_facet | Mira Siderova Georgi Shopov Gabriela Kehayova Stela Dragomanova |
| author_sort | Mira Siderova |
| collection | DOAJ |
| description | The aim of this study was to evaluate the antidiabetic therapy during hospitalization, as well as that recommended at discharge from a single university endocrinology clinic for all type 2 diabetes patients admitted over a 12-month period. Of the 464 cases, 345 (74.4%) were emergency admissions and 119 (25.6%) were planned hospitalizations for poor glycemic control. At discharge, one antidiabetic medication was prescribed in 133 patients (28.7%), two in 169 (36.3%), three in 103 (22.2%), and 48 (10.4%) received four or more glucose-lowering agents. Of all patients, 175 (37.7%) were taking sodium-glucose cotransporter 2 inhibitors (SGLT2i), 71 (15.3%) glucagon-like peptide 1 receptor agonists (GLP1-RAs), and 42 (9.1%) both organ-protective classes. Among patients with concomitant cardiovascular disease, chronic kidney disease, or both (n = 300; 64.7%), SGLT2i was prescribed in 150 (50.0%), GLP1-RA in 51 (17.0%), and both in 34 individuals (11.3%). Our results indicate that more than half of the patients at cardio-renal risk (55.7%) received at least one organ-protective medication. |
| format | Article |
| id | doaj-art-0edcb49fc12844ab99e082d5a12f6184 |
| institution | Kabale University |
| issn | 2603-557X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Pensoft Publishers |
| record_format | Article |
| series | Pharmacia |
| spelling | doaj-art-0edcb49fc12844ab99e082d5a12f61842025-08-20T03:33:21ZengPensoft PublishersPharmacia2603-557X2025-07-01721710.3897/pharmacia.72.e163319163319Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experienceMira Siderova0Georgi Shopov1Gabriela Kehayova2Stela Dragomanova3UMHAT “St. Marina”UMHAT “St. Marina”Medical University “Prof. Dr. Paraskev Stoyanov”Medical University “Prof. Dr. Paraskev Stoyanov”The aim of this study was to evaluate the antidiabetic therapy during hospitalization, as well as that recommended at discharge from a single university endocrinology clinic for all type 2 diabetes patients admitted over a 12-month period. Of the 464 cases, 345 (74.4%) were emergency admissions and 119 (25.6%) were planned hospitalizations for poor glycemic control. At discharge, one antidiabetic medication was prescribed in 133 patients (28.7%), two in 169 (36.3%), three in 103 (22.2%), and 48 (10.4%) received four or more glucose-lowering agents. Of all patients, 175 (37.7%) were taking sodium-glucose cotransporter 2 inhibitors (SGLT2i), 71 (15.3%) glucagon-like peptide 1 receptor agonists (GLP1-RAs), and 42 (9.1%) both organ-protective classes. Among patients with concomitant cardiovascular disease, chronic kidney disease, or both (n = 300; 64.7%), SGLT2i was prescribed in 150 (50.0%), GLP1-RA in 51 (17.0%), and both in 34 individuals (11.3%). Our results indicate that more than half of the patients at cardio-renal risk (55.7%) received at least one organ-protective medication.https://pharmacia.pensoft.net/article/163319/download/pdf/ |
| spellingShingle | Mira Siderova Georgi Shopov Gabriela Kehayova Stela Dragomanova Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience Pharmacia |
| title | Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience |
| title_full | Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience |
| title_fullStr | Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience |
| title_full_unstemmed | Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience |
| title_short | Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience |
| title_sort | organ protective antidiabetic prescriptions in type 2 diabetes a single institution experience |
| url | https://pharmacia.pensoft.net/article/163319/download/pdf/ |
| work_keys_str_mv | AT mirasiderova organprotectiveantidiabeticprescriptionsintype2diabetesasingleinstitutionexperience AT georgishopov organprotectiveantidiabeticprescriptionsintype2diabetesasingleinstitutionexperience AT gabrielakehayova organprotectiveantidiabeticprescriptionsintype2diabetesasingleinstitutionexperience AT steladragomanova organprotectiveantidiabeticprescriptionsintype2diabetesasingleinstitutionexperience |